Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

CureVac (Germany) a clinical-stage biopharmaceutical companies focused on prophylactic and therapeutic vaccines for the treatment of prostate and non-small cell lung cancer, closed a $34.9M Series C financing. Participants include dievini Hopp BioTech Holding.

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Juvaris BioTherapeutics (Burlingame, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing, bringing the total round to $25M. Participants include Kleiner Perkins Caufield & Byers, SV Life Sciences and an undisclosed corporate partner.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Genticel (France) a clinical-stage biopharmaceutical company focused on therapeutic vaccines for the prevention of cervical cancer in HPV infected women, closed a $17.7M Series C financing. Participants include AGF Private Equity, Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio Fund and Edmond de Rothschild Investment Partners.

Archimedes Pharma (United Kingdom) a commercial-stage specialty oncology company focused on pain and critical care, closed a $99M Series C financing. Participants include Novo Growth Equity and Warburg Pincus.

Vaxart (San Francisco, CA) a preclinical-stage developer of a platform vaccine technology focusing on oral delivery that leverages an adjuvant based upon a toll-like receptor, closed a $12.5M Series B financing. Participants include Care Capital.

Immune Targeting Systems (United Kingdom) a clinical-stage biopharma focused on synthetic vaccines for seasonal influenza strains, closed a $13.2M Series A financing, bringing the total round to $20.2M. Participants include Novartis Venture Funds, HealthCap, Truffle Capital and London Technology Fund.